The University of Chicago Medicine’s Center for Personalized Therapeutics is hosting a virtual summit from June 9 to July 1 to discuss interventional pharmacoeconomics.
Topics include the efficacy and safety of third-line treatment regimens in resource-limited settings, viral rebound rates after treatment interruption of modern ART, and whether a standardized frailty score can improve clinicians’ ability to estimate cardiovascular risk among older people with HIV.
The Outcomes Related to COVID-19 Treated with Hydroxychloroquine among In-patients with Symptomatic Disease (ORCHID) trial stopped enrolling new patients based on the fourth scheduled interim analysis showing no evidence of benefit or harm.
Administering the MMR (measles, mumps, rubella) vaccine could serve as a preventive measure to dampen septic inflammation associated with COVID-19 infection, say a team of experts in this week's mBio, a journal of the American Society for Microbiology.
Mount Sinai Health System is beginning the first clinical trial in the New York metropolitan region of an immune-boosting therapy in COVID-19 patients.
A major study investigating the effectiveness of liver perfusion as a technique to improve the function of donor livers that would have otherwise been rejected has shown that up to 7 in every 10 could be used after just 4-6 hours of the assessment.
A first-in-class clinical trial suggests a novel treatment measurably slowed progression of non-alcoholic fatty liver disease to its more progressive and deadly form.
Results from a six-month, multi-site clinical trial called the Wireless Innovation for Seniors with Diabetes Mellitus (WISDM) Study Group have been published by the Journal of the American Medical Association (JAMA).
MD Anderson and Philips today announced a collaboration to aid oncologists around the world to personalize therapy based on their patients' genomic profiles, with the aim of improving patient care.
A phase I/II clinical trial by researchers at Stanford University suggests that vaccines prepared from a patient’s own tumor cells may prevent the incurable blood cancer mantle cell lymphoma (MCL) from returning after treatment. The study, which will be published June 19 in the Journal of Experimental Medicine (JEM), reveals that the vaccines are a safe and effective way to induce the body’s immune system to attack any tumor cells that could cause disease relapse.
Researchers from Nationwide Children’s Hospital have published in JAMA Neurology results from the first four patients treated in the first clinical trial of systemic delivery of micro-dystrophin gene therapy in children with Duchenne muscular dystrophy (DMD) – and initial findings suggest that the therapy can provide functional improvement that is greater than that observed under the standard of care.
Researchers at UC San Diego School of Medicine, with colleagues elsewhere, will receive almost $19 million over five years for the fourth phase of the Vietnam Era Twin Study of Aging, which investigates cognition, aging and the risk for mild cognitive impairment and Alzheimer’s disease.
The University of Illinois at Chicago will soon test a vaccine for COVID-19. Expected to launch July 9, the trial — a phase 3 clinical study — will test the efficacy of a vaccine developed by biotech company Moderna.
Berzosertib, an ATR-targeting drug, improves progression-free survival in combination with chemotherapy in patients with high-grade serous ovarian cancer
Atlantic Health System Cancer Care will continue its tradition of world-class medical education with its 2020 Annual Review in Oncology Virtual Symposium. The symposium, held virtually this year with free registration, will take place Saturday, June 27, 2020, from 8 a.m. to 12:30 p.m. ET. Distinguished faculty from some of the Northeast’s leading cancer centers will summarize the latest advances in oncology, which have recently been presented at international conferences. The diverse range of topics should be of interest to surgeons, medical and radiation oncologists and other physicians, nurses and allied health professionals.
UVA Health and UVA Children’s are increasing access to the latest food allergy clinical trials and expanding their cutting-edge food-allergy research, following their selection to a national food-allergy clinical network.
Most of the registered clinical trials of potential treatments for COVID-19 underway as of late March were designed in ways that will greatly limit their value in understanding potential treatments, according to a study from researchers at Johns Hopkins Bloomberg School of Public Health.
The first convalescent plasma transfusion trial results from Houston Methodist have been published. Of the study’s 25 patients, 19 have improved and 11 discharged. With no adverse side effects caused by the therapy, the study concluded convalescent plasma is a safe treatment option for patients with severe COVID-19. This is the first peer-reviewed publication in the U.S. of convalescent plasma therapy results for COVID-19.
As a leading New Jersey academic medical center and member of Hackensack Meridian Health, Jersey Shore University Medical Center is able to provide its patients access to existing clinical trials and the latest medical techniques in a variety of specialties. Currently, the medical center is recruiting individuals who have been clinically diagnosed with COVID-19 or have laboratory test results showing they have COVID-19 antibodies to donate their blood and potentially assist patients in their recovery from the virus.
Today, University of Minnesota Medical School researchers published the results from the first randomized clinical trial testing hydroxychloroquine for the post-exposure prevention of COVID-19.
Rutgers Cancer Institute expert discusses guarding data integrity for the first remdesivir double-blind placebo-controlled clinical trial addressing treatment for COVID-19.
The University of Texas MD Anderson Cancer Center and Rakuten Medical, Inc. today announced a strategic alliance collaboration agreement to advance the development of new cancer therapies based on Rakuten Medical’s proprietary IlluminoxTM technology platform.
The COVID Research Program is rapidly enrolling patients from New Jersey, which has one of the world’s highest concentrations of COVID-19 patients. Atlantic Health System offers a study sponsored by TScan Therapeutics, Inc., a leading T cell therapeutics company in Waltham, Massachusetts, focused on identifying the precise way the human immune system recognizes and responds to infections like COVID-19 or other diseases, like cancers. TScan has developed a novel technology that enables them to identify the natural targets of T cells.
A review of 56 randomized clinical trials finds that psychological and behavioral therapies may be effective non-drug treatments for reducing disease-causing inflammation in the body.
The University of Kentucky and ArtemiLife Inc. will collaborate on a clinical study using the extract of a medicinal plant grown in Kentucky to test for anti-cancer activity of Artemisia annua and to determine the recommended dose of Artemisia annua for future clinical trials.
Researchers at Tulane University School of Medicine identified a gene that causes an aggressive form of breast cancer to rapidly grow. More importantly, they have also discovered a way to “turn it off” and inhibit cancer from occurring. The animal study results have been so compelling that the team is now working on FDA approval to begin clinical trials and has published details in the journal Scientific Reports.
How might the novel coronavirus be prevented from entering a host cell in an effort to thwart infection? A team of biomedical scientists has made a discovery that points to a solution.
A $1M gift from the John and Mary Tu Foundation is accelerating the efforts of UC San Diego translational research virologist Davey Smith to increase the number of people tested for COVID-19, as well as develop new ways to track and treat the virus. Smith and his team are studying how the disease spreads to better inform contact tracing, as well as leading clinical trials to test new drugs for treatment of COVID-19.
The first patients were treated as part of a clinical trial testing whether an antibody therapy can safely reduce COVID-19 disease severity. The experimental treatment consists of identical copies of an antibody, a blood protein related to those that occur naturally as part of the human immune system, researchers say.
Findings and the development of a new international consortium known as HoLISTIC are being shared as part of a poster presentation at the virtual 2020 American Society for Clinical Oncology Annual Meeting taking place this week.
By analyzing tumors from patients treated with immunotherapy for advanced kidney cancer in three clinical trials, Dana-Farber Cancer Institute scientists have identified several features of the tumors that influence their response to immune checkpoint inhibitor drugs.
Due to the devastating worldwide impact of COVID-19, the illness caused by the SARS-CoV-2 virus, there has been unprecedented efforts by clinicians and researchers from around the world to quickly develop safe and effective treatments and vaccines.
Results of an Electronic Health Record (EHR) study assessing the most commonly used medications for raising blood pressure in patients with nontraumatic subarachnoid hemorrhage (SAH), a rare type of stroke, have been published in Neurosurgical Focus by scientists at The University of Texas Health Science Center at Houston (UTHealth).
Patients with advanced non-small cell lung cancer (NSCLC) and the MET exon 14 (METex14) skipping mutation had a 46.5% objective response rate to the targeted therapy drug tepotinib, as shown in a study published today in the New England Journal of Medicine and presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 9556 – Poster 322) by researchers from The University of Texas MD Anderson Cancer Center.
The targeted therapy pralsetinib appears to have high response rates and durable activity in patients with a broad variety of tumors harboring RET gene fusions, according to results from the international Phase I/II ARROW trial, led by researchers at The University of Texas MD Anderson Cancer Center.
The adoptive T-cell therapy ADP-A2M4, which is engineered to express a T-cell receptor (TCR) directed against the MAGE-A4 cancer antigen, achieved responses in patients with multiple solid tumor types, including synovial sarcoma, head and neck cancer and lung cancer, according to results from a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.
Results of a Phase I clinical trial conducted by researchers at the Yale Cancer Center have shown that ARV-110, an androgen receptor PROTAC® protein degrader, demonstrates anti-tumor responses in patients with metastatic castration-resistant prostate cancer.
A Georgetown University Medical Center clinical trial investigating the cancer drug nilotinib in people with Alzheimer’s disease finds that it is safe and well-tolerated, and researchers say the drug should be tested in a larger study to further determine its safety and efficacy as a potential disease-modifying strategy.
During a plenary session of the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, findings will be presented from the global phase III JAVELIN Bladder 100 randomized study conducted by investigators from Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center and University of Washington Medicine along with several other research centers. The results demonstrated significantly prolonged overall survival of patients with locally advanced (unresectable) or metastatic urothelial cancer when treated with first-line immunotherapy avelumab plus best supportive care (BSC) compared to BSC alone (following disease control on induction chemotherapy).
Dr. Alistar has pioneered the use of CPI-613® (devimistat), a unique first-in-class treatment for locally advanced or metastatic pancreatic cancer, in combination with two chemotherapy drugs. Devimistat uniquely targets enzymes involved in cancer cell metabolism, against pancreatic cancer. The study’s efficacy data suggest devimistat has synergy with chemotherapy.The current study was funded by the drug’s manufacturer, New Jersey-based Rafael Pharmaceuticals and by Atlantic Health System.
According to findings led by researchers at Yale Cancer Center, treatment with the targeted therapy osimertinib following surgery significantly improves disease-free survival (DFS) in patients with early-stage, non-small cell lung cancer (NSCLC) with EGFR gene mutations.
Men who tested positive for COVID-19 are now being enrolled in a unique study led by the University of Miami Miller School of Medicine to determine the interaction of the virus with semen.
University of Colorado Cancer Center team uses liquid biopsy to predict multiple myeloma drug resistance and sensitivity.
A combination therapy of ivosenidib (IVO) plus venetoclax (VEN) with or without azacitidine (AZA) was found to be effective against a specific genetic subtype of acute myeloid leukemia (AML) in a Phase Ib/II trial led by researchers at The University of Texas MD Anderson Cancer Center. The results of this trial may support a novel course of action for patients with AML harboring an IDH1 mutation who have historically had few treatment options.
In an international trial led by researchers at The University of Texas MD Anderson Cancer Center, treatment with MK-6482, the small molecule inhibitor of hypoxia-inducible factor (HIF)-2a was well tolerated and resulted in clinical responses for patients with von Hippel-Lindau disease (VHL)–associated renal cell carcinoma (RCC).
Nine top universities and hospitals have launched a social movement and free tool to match the public with health research opportunities that need volunteers in the hunt to discover treatments, vaccines, and what the pandemic’s long-term impacts will be on survivors.
Penn State Health Milton S. Hershey Medical Center has enrolled its first patients in the continuation of a clinical trial using the investigational antiviral drug remdesivir for treatment of COVID-19.
In this study, researchers investigated if specific targeting of CD133+ glioblastoma with cutting-edge immunotherapy drugs could eradicate the most aggressive subpopulation of cells in the tumour. They also looked at the safety of CD133-targeting therapies on normal, non-cancerous human stem cells including hematopoietic stem cells which create blood cells and progenitor cells which can form one or more kinds of cells.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right